Mereo BioPharma Group plc Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q1 2023 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Mereo BioPharma Group plc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q1 2023 to Q2 2024.
- Mereo BioPharma Group plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2024 was -$12.3M, a 3390% decline year-over-year.
- Mereo BioPharma Group plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$25.3M, a 52.2% increase from 2022.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)